Nureca Ltd. (NURECA) AI Stock Analysis

• Market Cap: ₹3.02B
• Dividend Yield: N/A
• Average Volume (3M): 8.05K
• Price to Earnings (P/E): 73.6
• Beta (1Y): 0.91
• Revenue Growth: 43.30%
• EPS Growth: N/A
• Country: IN
• Employees: 138
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 3.63
• Shares Outstanding: 10,000,175
• 10 Day Avg. Volume: 21,278
• 30 Day Avg. Volume: 8,053
• PEG Ratio: -1.76
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 2.00
• P/FCF Ratio: -9.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: ₹335.00 ▲(16.40% Upside)

Nureca Ltd.'s overall stock score is primarily impacted by its financial performance challenges, including declining revenues and cash flow issues. While technical indicators show positive momentum, the high P/E ratio suggests overvaluation. The lack of earnings call data and corporate events limits additional insights.

Nureca Ltd. Business Overview & Revenue Model

Company Description

Nureca Limited, a B2C company, engages in the home healthcare and wellness products business in India. It offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeter, glucose meter, and thermometer; orthopedic products, including massagers, pain monitors, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise, fitness tracking, and dental and personal care products. The company also provides mother and baby care products comprising baby feeding, carry cots, baby skincare, and bottle warmers and steamers; nutritional supplements and weight management products; and ECG, fitness tracker, and smart weighing scale products. Nureca Limited offers its products under Dr Trust, Dr Physio, and Trumom brands. The company sells its products through third party e-commerce players, distributors, and retailers; and through its website, drtrust.in. Nureca Limited was incorporated in 2016 and is based in Chandigarh, India.

How the Company Makes Money

Nureca generates revenue primarily through the sale of its healthcare and wellness products, which are marketed through various channels, including e-commerce platforms, retail partnerships, and direct-to-consumer sales. The company employs a multi-channel distribution strategy to reach a broader customer base and increase sales volume. Additionally, Nureca may explore revenue opportunities through strategic partnerships with healthcare providers and institutions, which can facilitate bulk purchases and enhance brand visibility. The company's focus on product innovation and customer engagement also plays a critical role in driving repeat sales and fostering brand loyalty, contributing significantly to its overall earnings.

Nureca Ltd. Financial Statement Overview

Summary

Nureca Ltd. shows strong equity and low leverage, but faces challenges with declining revenues, negative profitability, and cash flow issues. Operational efficiency and cash management improvements are essential.

Income Statement

Nureca Ltd. has shown volatile revenue trends with a decline in revenue from 2022 to 2025. The gross profit margin remains moderate at approximately 38% in 2025, but net profitability is a concern with fluctuating net income, swinging to losses in recent periods. The EBIT margin is negative, indicating operational challenges. EBITDA shows improvement in 2025 compared to previous years, but overall performance remains inconsistent.

Balance Sheet

Nureca Ltd.'s balance sheet showcases strong equity with a high equity ratio of around 92% in 2025, indicating low leverage. The debt-to-equity ratio is favorable, suggesting prudent debt management. However, declining total assets over recent periods may signal underlying issues in asset management or utilization.

Cash Flow

The cash flow analysis reveals a challenging financial position with negative free cash flow growth and operating cash flow. The free cash flow to net income ratio is unfavorable, highlighting inefficiencies in converting income to cash. Despite some capital investment, liquidity remains a concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.24B	1.10B	919.28M	1.11B	2.56B	2.13B
Gross Profit	413.64M	231.33M	311.42M	355.94M	1.23B	1.14B
EBITDA	34.81M	48.95M	2.41M	-79.04M	632.04M	636.83M
Net Income	-30.00K	8.46M	-17.94M	-82.50M	449.60M	463.74M
Balance Sheet
Total Assets	0.00	2.10B	2.05B	2.07B	2.19B	1.86B
Cash, Cash Equivalents and Short-Term Investments	1.23B	736.29M	1.44B	1.02B	927.10M	1.27B
Total Debt	0.00	49.66M	25.16M	33.27M	44.05M	38.85M
Total Liabilities	-1.94B	156.91M	120.54M	116.97M	159.32M	226.54M
Stockholders Equity	1.94B	1.94B	1.93B	1.95B	2.03B	1.63B
Cash Flow
Free Cash Flow	0.00	-234.06M	-37.98M	98.31M	-46.00M	341.40M
Operating Cash Flow	0.00	-190.83M	-27.12M	102.27M	13.99M	348.67M
Investing Cash Flow	0.00	84.39M	175.76M	-164.56M	-30.89M	-1.10B
Financing Cash Flow	0.00	-1.69M	-13.03M	-15.07M	-73.02M	923.39M

Nureca Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 287.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Positive. The current price of 287.8 is above the 20-day moving average (MA) of 252.99, above the 50-day MA of 248.58, and above the 200-day MA of 262.24, indicating a bullish trend. The MACD of 17.27 indicates Negative momentum. The RSI at 65.89 is Neutral, neither overbought nor oversold. The STOCH value of 74.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NURECA.

Nureca Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVENZYMES	65 Neutral	₹34.85B	25.58	―	1.71%	5.89%	-1.30%
MOREPENLAB	62 Neutral	₹26.79B	28.69	―	0.41%	2.12%	-25.99%
SOLARA	53 Neutral	₹28.86B	113.29	―	―	-7.29%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZOTA	51 Neutral	₹46.78B	―	―	0.06%	82.58%	-63.05%
NURECA	49 Neutral	₹3.02B	73.62	―	―	43.30%	―
INDOCO	45 Neutral	₹26.35B	96.22	―	0.07%	-8.28%	-246.17%

Nureca Ltd. Corporate Events

Nureca Ltd. Releases Q2 and Half-Year Financial Results

Nureca Ltd. announced the approval of its unaudited standalone and consolidated financial results for the second quarter and half-year ending September 30, 2025. The financial results, which include the cash flow statement and statement of assets and liabilities, were reviewed by the Board of Directors in a meeting held on October 16, 2025. The announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, maintaining transparency and compliance with regulatory requirements.

Nureca Limited Announces CFO Resignation

Nureca Limited announced the resignation of its Chief Financial Officer, Naresh Gupta, effective January 9, 2026. This change in leadership is part of the company’s ongoing adjustments and is not attributed to any material reasons beyond those stated in Gupta’s resignation letter. The transition is expected to be managed smoothly, ensuring minimal disruption to Nureca’s operations and strategic objectives.